Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)
Barcelona, Spain:
Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease1.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617437460/en/
Ferrer's pharmaceutical production plant in Sant Cugat del Vallés, Barcelona, Spain.
'We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our purpose of using business to fight for social justice, we are committed to advancing this promising therapy as quickly as possible to benefit as many patients as possible,' said Mario Rovirosa, Chief Executive Officer of Ferrer.
Fast Track designation is a significant milestone in the drug development process. It is a program that offers the possibility of having more frequent meetings with the FDA to discuss the drug's development, eligibility for Accelerated Approval and Priority Review if relevant criteria are met.
'This designation underscores the importance of expediting the development and review of FNP-223 to address critical unmet needs in patients with this rare and devastating disease,' said Marta Parmar, Ferrer's Chief Quality, Regulatory and Pharmacovigilance Officer.
Progressive supranuclear palsy manifests in patients with symptoms such as difficulty speaking, imbalance, changes in gait, cognitive problems2-4. PSP has a prevalence of approximately 5 cases per 100,000 people and primarily affects individuals over the age of 603. The disease's etiology is believed to be related to the abnormal accumulation of tau proteins in certain areas of the brain, leading to neurodegeneration3,4. Preclinical models have demonstrated that FNP-223 can prevent the abnormal accumulation of tau proteins in neurons5. Ferrer now aims to show that this molecule is safe and effective in patients with PSP.
Oscar Pérez, Chief Scientific Officer of Ferrer, also expressed his enthusiasm: 'Receiving Fast Track designation is a significant milestone in our journey to provide a transformative treatment for PSP. We are excited to advance our research and hopefully offer a new therapeutic option earlier for patients living with this challenging condition.'
About FNP-223
FNP-223 is a new orally administered chemical compound that functions as a reversible and substrate-competitive inhibitor of the O-GlcNAcase (OGA) enzyme5. Mechanistically, FNP-223 binds to the active site of OGA enzyme. As a result, the inhibitor prevents the substrate from accessing the catalytic pocket, thereby impeding the removal of O-GlcNAc modifications from natural client proteins such as the tau protein. Inhibiting O-GlcNAcase is expected to cause a rapid increase of O-GlcNAcylated (glycosylated) tau proteins, ultimately leading to a reduction in abnormal aggregated tau as neurofibrillary tangles (NFT) over a certain period5.
Bibliography:
1. ClinicalTrials.gov A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER). ClinicalTrials.gov [Internet]. Available from: https://www.clinicaltrials.gov/study/NCT06355531 .
2. Coughlin DG, Litvan I. Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism Relat Disord. 2020 Apr;73:105-116. doi: 10.1016/j.parkreldis.2020.04.014. Epub 2020 May 25.
3. Agarwal S, Gilbert R. Progressive Supranuclear Palsy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526098/ .
4. Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Pract Neurol. 2021;21(5):376-383. doi: 10.1136/practneurol-2020-002794.
5. Permanne B, Sand A, Ousson S, Nény M, Hantson J, Schubert R, et al. D. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies. ACS Chem Neurosci. 2022 Apr 20;13(8):1296-1314. doi: 10.1021/acschemneuro.2c00057.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617437460/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Incyte announces FDA extends review period for Opzelura sNDA
The company states: 'Incyte (INCY) announced that the FDA has extended the review period for the supplemental New Drug Application, sNDA, for ruxolitinib cream, Opzelura, a topical Janus kinase inhibitor, for the treatment of children 2-11 years old with mild to moderate atopic dermatitis. The PDUFA action date has been extended by three months to September 19, 2025. The FDA extended the PDUFA action date to allow time to review additional chemistry, manufacturing and controls data on the 0.75% strength submitted by Incyte in response to a recent FDA information request.' Steven Stein, M.D., Chief Medical Officer, Incyte stated: 'We are confident in the potential of ruxolitinib cream to become an important non-steroidal, topical treatment option for pediatric patients with atopic dermatitis and we will continue to work closely with the FDA to ensure the Agency has all of the information needed to complete its review.' Confident Investing Starts Here:
Associated Press
6 hours ago
- Associated Press
IBN Coverage: HeartBeam (NASDAQ: BEAT) Earns FDA Clearance for First Cable-Free ECG System for Arrhythmia Detection
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 20, 2025 ( NEWMEDIAWIRE ) - HeartBeam (NASDAQ: BEAT) announced it has received FDA 510(k) clearance for its flagship ECG system, a first-of-its-kind, credit card-sized, cable-free device designed to deliver high-fidelity, three-directional cardiac recordings for arrhythmia evaluation. The clearance marks a major regulatory milestone and accelerates HeartBeam's plans to improve access to timely, remote cardiac care. When symptoms arise, patients use the app-guided system to record a 30-second ECG, which is automatically uploaded to the cloud for physician review in the context of medical history. The company will soon launch an Early Access Program to engage early adopters and providers ahead of broader commercialization. This foundational clearance also sets the stage for future advancements, including 12-lead ECG synthesis, AI-based arrhythmia detection, and remote heart attack risk scoring. HeartBeam's long-term vision is to revolutionize cardiac care by enabling continuous, predictive insights outside traditional clinical settings. To view the full press release, visit About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care - all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to BEAT are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected]
Associated Press
6 hours ago
- Associated Press
Murphy Business Sales Richardson Franchise Celebrates 17 Years of Helping Businesses Sell Smarter
06/20/2025, Richardson, Texas // PRODIGY: Feature Story // Murphy Business Sales franchise of Richardson, Texas, led by Douglas R. Batts Sr., MBA, celebrates its milestone of 17 years in navigating uncharted waters, especially for small business owners unsure of their company's true value. This brokerage firm has helped sellers make it to safe harbor, backed by data, integrity, and deep industry knowledge. Douglas R. Batts Sr., MBA Batts acquired the Richardson franchise operations in 2008. Since then, his franchise has grown into one of the top-performing offices in the Murphy network, which spans over 175 franchises across the U.S. and Canada. With more than $40 million in closed transaction value under his belt and a reputation for ethical, full-service brokerage, Batts is known for helping business owners sell with confidence and realism. 'Most companies don't sell because they're overpriced or have bad financials,' Batts explains. 'We simply won't take a business to market unless we believe it's priced fairly and the books are solid. It's a standard all Murphy Business Sales brokers take seriously, and that credibility is what sets us apart with both buyers and lenders.' The broker agency offers a true end-to-end process: assessing business readiness, conducting valuations, crafting marketing materials, qualifying buyers, arranging financing, and managing the closing and escrow process. Batts is licensed in Texas, Florida, South Dakota, and soon Georgia. While he serves clients within his own territory, he notes that the Murphy Business Sales network allows for co-brokered deals across the U.S. and Canada. What makes his operation stand out in the market, Batts says, is how his team brings the Murphy Business Sales' values to life through a consistent commitment to thorough, professional, and ethical transactions. He states, 'We work with sellers to prepare them before ever going to market. That includes cleaning up financials, managing expectations, and ensuring everything is in place to attract serious buyers.' One of the biggest hurdles Batts encounters is the unrealistic expectations some sellers have about their business's value. 'I've had clients tell me their business is worth a million dollars because that's what they need to retire,' Batts says. 'But that's not how valuations work.' Instead, his team gathers financial statements, tax returns, and profit and loss statements to analyze a business's true earnings performance. They use industry-standard metrics, such as seller's discretionary earnings (SDE) or recasted EBITDA, and compare those against similar transactions to arrive at a fair market value. The result is a credible, data-supported valuation that has greater credibility with buyers, lenders, and attorneys. This rigorous valuation process is delivered through a Broker's Opinion of Value or Certified Valuation Reports, depending on the client's needs. Murphy Business also partners with preferred SBA lenders to pre-qualify businesses, enhancing buyer confidence and reducing time to close. Once a business is ready for market, Murphy Business Sales taps into its vast network of brokers and hundreds of qualified buyers. Listings are shared confidentially across a proprietary MLS-style platform and up to a dozen external websites, with each listing accompanied by a detailed Confidential Information Memorandum. 'We know how to reach serious buyers,' Batts confirms. 'We also know how to protect confidentiality throughout the process, which is critical for business continuity.' Batts and his team often serve as intermediaries, working between buyer and seller to structure deals, refer legal professionals, and facilitate financing. They also stay involved all the way to escrow, ensuring that asset transfers go smoothly. The Richardson-based franchise's success has earned Batts awards within the Murphy network. But Batts attributes his success less to accolades and more to the foundational principles of trust, ethics, results, and transparency. 'Everything starts with credibility,' he says. 'If you're trying to sell a business and the price isn't defensible, or the financials are not in order, you're going to struggle. We make sure our clients are positioned for success before we ever take them to market.' For business owners considering a sale in the future, Batts offers clear advice: get the books in order, get a professional valuation, and don't try to go at it alone. 'Selling your business is probably one of the most important financial decisions of your life,' he says. 'You need someone who knows how to defend a valuation, who has the buyer network, and who understands how to navigate negotiations. That's what we do.' And with a track record spanning more than 17 years, Batts' Murphy Business Sales franchise is proving that experience, ethics, and data-driven strategy can create a winning formula, no matter where a business calls home. Media Contact Email: Name: Douglas R. Batts Sr. MBA Email: [email protected] Source published by Submit Press Release >> Murphy Business Sales Richardson Franchise Celebrates 17 Years of Helping Businesses Sell Smarter
